JNJ Dec 2026 195.000 call
| Previous close | 3.9000 |
| Open | N/A |
| Bid | 2.0200 |
| Ask | 5.1000 |
| Strike | 195.00 |
| Expiry date | 2026-12-18 |
| Day's range | 3.9000 - 3.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Investor's Business DailyHow Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin
Small biotech company Halozyme is behind some of the biggest names in medicine, including Johnson & Johnson's Darzalex and Roche's Tecentriq.
PR NewswireCARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
Johnson & Johnson (NYSE:JNJ) announced today positive results from a prespecified second interim analysis of the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) compared to standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) for the treatment of patients with relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy. The interim analysis showed a statistically
ZacksMerck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.
